Factores que inciden en las dificultades de convivencia escolar en los niños y las niñas de 6 y 7 años de edad del Colegio Nueva Generación del municipio de Itagüí

Determinar los factores que inciden en las dificultades de convivencia escolar entre los niños y las niñas de 6 y 7 años de edad del colegio nueva generación del municipio de Itagüí.El presente trabajo de investigación se llevó a cabo con el fin de mejorar un sano ambiente escolar,el cual tratósobre los factores que inciden en las dificultades de convivencia escolar en los niños y las niñas de 6 y 7 años de edad del colegio nueva generación del municipio de Itagüí. En el cual observamos algunas falencias en cuanto a la convivencia escolar en donde se presenta la falta de respeto y autocontroly graves problemas dentro y fuera del aula de clase de los niños y niñas del grado primero.Se observóen ellos la falta de trabajo colaborativo y la falta de comunicación entre los estudiantes, el pocotiempo que le dedican los padres a sushijos ya sea por trabajo u otras ocupaciones llenado estos vacíos con cosas materiales con las cuales ellos se puedan sentir entretenidos,de talmanera se ve que muchos son cuidados por otras personas ya sea vecinos, abuelos u otras personas que no tienen unas normas establecidas en casa y muchas de estas personas optan por la sobreprotección como el factor de crianza.El trabajo de investigación se realizó desde un enfoque de investigación cualitativo.Parala realización de este trabajo de investigaciónse siguió un proceso riguroso, dinámico y continuo, en donde se desarrollaron una serie de etapas relacionadas entre sí, con el propósito de llegar a interpretar lo planteado en el objetivo general y aportar a los procesos convivenciales del colegio. Porúltimo se creó un proyecto de intervención titulado “Las inteligencias múltiples como estrategia para favorecer conocimiento de las emociones y mejorar la convivencia escolar”

SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics

INTRODUCTION: Despite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data. METHODS: We present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online registry created in 2010 to track antipsychotic adverse effects in Spanish youth <18 years old currently taking or initiating with any antipsychotic treatment. SENTIA collects information on sociodemographic, diagnostic and treatment characteristics, past personal medical/psychiatric history, healthy lifestyle habits and treatment adherence. Additionally, efficacy and adverse effect data are recorded including the Children’s Global Assessment Scale; Clinical Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, vital signs, blood pressure, and EKG. Finally, fasting blood is drawn for hematology, electrolytes, renal, liver and thyroid function, glucose, insulin, lipid, prolactin and sex hormone levels. Initially, a diagnostic interview and several psychopathology scales were also included. Patients are assessed regularly and followed even beyond stopping antipsychotics. RESULTS: Since 01/17/2011, 85 youth (11.5 ± 2.9 (range = 4-17) years old, 70.6% male) have been included at one inaugural center. After a mean duration of 17 ± 11 (range = 1-34) months, 78.8% are still actively followed. For feasibility reasons, the diagnostic interview and detailed psychopathology scales were dropped. The remaining data can be entered in <30 minutes. Several additional centers are currently being added to SENTIA. CONCLUSIONS: Implementation of a systematic online pharmacovigilance system for antipsychotic adverse effects in youth is feasible and promises to generate important information

Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial

Background and objectives: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels. Materials and methods: Four-hundred donors were enrolled in ConPlas-19. The presence and titres of anti-SARS-CoV-2 antibodies were evaluated by EUROIMMUN anti-SARS-CoV-2 S1 IgG ELISA. Results: A majority of 80.3% of ConPlas-19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti-SARS-CoV-2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24-3.42), with more than 7 days of COVID-19 symptoms (RR 1.89; 95% CI 1.05-3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16-5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91-3.06). Conclusion: SARS-CoV-2 CP candidate donors' age, duration of COVID-19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID-19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks.European Regional Development Fund (FEDER); Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, Grant/Award Number: COV20/00072; SCReN (Spanish Clinical Research Network), Instituto de Salud Carlos III, Grant/Award Number: PT17/0017/0009S

Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): Study protocol for a randomized controlled trial

Background: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another. Methods/Design: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015. Discussion: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendationsThe study has been funded by two national grants from the Spanish Ministry of Health and ISCIII

Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study: Real world evidence from one Latin American country

Introducción: Durante la pandemia, se ha recomendado que la vacunación contra COVID-19 sea una prioridad para los pacientes con cáncer; sin embargo, estos pacientes no se incluyeron en los estudios iniciales de evaluación de las vacunas disponibles. Objetivo: Definir el impacto de la vacunación contra COVID-19 en la prevención del riesgo de complicaciones asociadas a la infección en una cohorte de pacientes con cáncer en Colombia. Métodos: Se realizó un estudio observacional analítico de cohorte, basado en el registro nacional de pacientes con cáncer e infección por COVID 19 ACHOC-C19. Los datos se recolectaron desde junio de 2021, hasta octubre de 2021. Los criterios de inclusión fueron: Pacientes mayores de 18 años con diagnóstico de cáncer e infección confirmada por COVID-19. Se compararon los datos de las cohortes no vacunadas y vacunadas. Los resultados evaluados incluyeron mortalidad por todas las causas en los 30 días siguientes al diagnóstico de COVID-19, hospitalización y necesidad de ventilación mecánica. La estimación del efecto se realizó mediante el riesgo relativo (RR), la reducción absoluta del riesgo (RRA) y el número necesario a tratar (NNT). El análisis multivariante se realizó mediante modelos lineales generalizados. Resultados: Se incluyeron 896 pacientes, de los cuales 470 eran mayores de 60 años (52,4%) y el 59% eran mujeres (n=530). Se reclutaron 172 pacientes en la cohorte vacunada y 724 en la cohorte no vacunada (ratio: 1 a 4,2). La incidencia acumulada de resultados clínicos entre los pacientes no vacunados frente a los vacunados fue: para hospitalización 42% (IC 95%: 38,7%-46,1%) frente a 29%; (IC 95%: 22,4%-36,5%); para requerimiento de ventilación mecánica invasiva 8,4% (n=61) frente a 4,6% (n=8) y para mortalidad por todas las causas 17% (n=123) frente a 4,65% (n=8). Conclusiones: En nuestra población, los pacientes con cáncer no vacunados tienen un mayor riesgo de complicaciones por infección por COVID -19, como hospitalización, ventilación mecánica y mortalidad. Es muy recomendable promover activamente la vacunación entre esta población. El autor (es). Este es un artículo de acceso abierto distribuido bajo los términos de la Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). Consulte los términos y condicionesIntroduction: During the pandemic, it has been recommended that vaccination against COVID-19 be a priority for patients with cancer; however, these patients were not included in the initial studies evaluating the available vaccines. Objective: To define the impact of vaccination against COVID-19 in preventing the risk of complications associated with the infection in a cohort of patients with cancer in Colombia. Methods: An analytical observational cohort study, based on national registry of patients with cancer and COVID 19 infection ACHOC-C19, was done. The data was collected from June 2021, until October 2021. Inclusion criteria were: Patients older than 18 years with cancer diagnosis and confirmed COVID-19 infection. Data from the unvaccinated and vaccinated cohorts were compared. Outcomes evaluated included all-cause mortality within 30 days of COVID-19 diagnosis, hospitalization, and need for mechanical ventilation. The estimation of the effect was made through the relative risk (RR), the absolute risk reduction (ARR) and the number needed to treat (NNT). Multivariate analysis was performed using generalized linear models. Results: 896 patients were included, of whom 470 were older than 60 years (52.4%) and 59% were women (n=530). 172 patients were recruited in the vaccinated cohort and 724 in the non-vaccinated cohort (ratio: 1 to 4.2). The cumulative incidence of clinical outcomes among the unvaccinated vs vaccinated patients were: for hospitalization 42% (95% CI: 38.7%-46.1%) vs 29%; (95% CI: 22.4%-36.5%); for invasive mechanical ventilation requirement 8.4% (n=61) vs 4.6% (n=8) and for mortality from all causes 17% (n=123) vs 4.65% (n=8). Conclusion: In our population, unvaccinated patients with cancer have an increased risk of complications for COVID -19 infection, as hospitalization, mechanical ventilation, and mortality. It is highly recommended to actively promote the vaccination among this population. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions

A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol

ORTHOUNION is a multicentre, open, comparative, three-arm, randomized clinical trial (EudraCT number 2015-000431-32) to compare the efficacy, at one and two years, of autologous human bone marrow-derived expanded mesenchymal stromal cell (hBM-MSC) treatments versus iliac crest autograft (ICA) to enhance bone healing in patients with diaphyseal and/or metaphysodiaphyseal fracture (femur, tibia, and humerus) status of atrophic or oligotrophic nonunion (more than 9 months after the acute fracture, including recalcitrant cases after failed treatments). The primary objective is to determine if the treatment with hBM-MSCs combined with biomaterial is superior to ICA in obtaining bone healing. If confirmed, a secondary objective is set to determine if the dose of 100 × 106 hBM-MSCs is noninferior to that of 200 × 106 hBM-MSCs. The participants (n = 108) will be randomly assigned to either the experimental low dose (n = 36), the experimental high dose (n = 36), or the comparator arm (n = 36) using a central randomization service. The trial will be conducted in 20 clinical centres in Spain, France, Germany, and Italy under the same clinical protocol. The confirmation of superiority for the proposed ATMP in nonunions may foster the future of bone regenerative medicine in this indication. On the contrary, absence of superiority may underline its limitations in clinical use

Gestión del conocimiento. Perspectiva multidisciplinaria. Volumen 17

El libro “Gestión del Conocimiento. Perspectiva Multidisciplinaria”, Volumen 17 de la Colección Unión Global, es resultado de investigaciones. Los capítulos del libro, son resultados de investigaciones desarrolladas por sus autores. El libro es una publicación internacional, seriada, continua, arbitrada, de acceso abierto a todas las áreas del conocimiento, orientada a contribuir con procesos de gestión del conocimiento científico, tecnológico y humanístico. Con esta colección, se aspira contribuir con el cultivo, la comprensión, la recopilación y la apropiación social del conocimiento en cuanto a patrimonio intangible de la humanidad, con el propósito de hacer aportes con la transformación de las relaciones socioculturales que sustentan la construcción social de los saberes y su reconocimiento como bien público

OPAVA - UPPER SGUARE

Předmětem práce je návrh nové zástavby v centru města Opavy. Cílem řešení je zejména navrhnout urbanistickou strukturu vhodnou pro danou lokalitu a najít adekvátní funkční využití staveb posilující potenciál stagnujícího historického jádra města.The subject of my thesis is to design new city development in the Opava city centre. The goal is to design proper urban structure in that area and find adequate functions to increase the potenctial in the stagnating historical urban core